The Rare Disease Company Coalition represents life science companies that have brought 22 treatments to the market and have more than 160 rare disease development programs, according to the group. In 2020, coalition members invested more than $4.1 billion in research and development, representing approximately 65% of their annual operating budgets.

Working with policymakers to establish long-term, consistent, equitable and sustainable research incentives for rare diseases will be among the coalition's objectives.

Founding members of the Rare Disease Company Coalition include Acceleron Pharma, Aeglea BioTherapeutics, Agios Pharmaceuticals, Alnylam Pharmaceuticals, Harmony Biosciences, Orchard Therapeutics, Orphazyme US, Sarepta Therapeutics, Taysha Gene Therapies, and Ultragenyx Pharmaceutical.

New report investigates availability of orphan drugs
Findings of a new study commissioned by the National Organization for Rare Disorders explores the effect of patents and exclusivity on orphan drug products.

Global Genes produces series on gene therapy, editing
Rare disease patient advocacy organization Global Genes will publish a multimedia series about advances in gene therapy and gene editing technology throughout...

Development 'cookbooks' could speed up gene therapy
Great strides have been made in the development of gene editing tools in the past decade, but translating the technology into real therapies to treat...